BACKGROUND The concept of borderline lymphoproliferative disorder (LPD) has not been clearly defined. METHODS This study aimed to classify patients with leukemic LPD (n = 597, excluding hairy cell leukemia, mantle cell lymphomas, and CD10-positive LPDs) into CLL or non-CLL applying three diagnostic strategies (the D'Arena and CLLflow scores and CD43 expression) and to better characterize unclassified patients. RESULTS Patients with concurring CLL-like (n = 441) or non-CLL like (n = 99) results with the three diagnostic strategies were determined to have CLL and non-CLL, respectively. Patients with discordant results (n = 57) were analyzed taking into consideration each individual cytometric marker and cytogenetic data: 41 were classified (11 CLL, 30 non-CLL) and 16 (2.7% of the entire series) could not and were considered borderline LPD. Excluding borderline LPD, the CLLflow score had the highest accuracy of the three strategies. With the addition of CD43 no patient was misclassified. With the aid of hierarchical clustering, 12 of the 16 borderline patients seemed to fall into two well-defined antigenic groups. None of the diagnostic strategies could reliably pick out borderline LPD. CONCLUSION The combination of the CLLflow score and CD43 generally has a high diagnostic accuracy for leukemic LPD but it is not reliable to identify or diagnose borderline LPD. This latter group needs further study to determine its underlying biology. © 2018 International Clinical Cytometry Society.

中文翻译：

---

完善边缘性淋巴增生性疾病的界限。

背景技术尚未明确定义边缘性淋巴增生性疾病（LPD）的概念。方法本研究旨在通过三种诊断策略（D'Arena和CLLflow评分以及CD43）将白血病LPD（n = 597，不包括毛细胞白血病，套细胞淋巴瘤和CD10阳性LPD）的患者分类为CLL或非CLL。表达式），以更好地表征未分类的患者。结果三种诊断策略同时获得CLL样（n = 441）或非CLL样（n = 99）的患者分别被确定为CLL和非CLL。对结果不一致的患者（n = 57）进行了分析，并考虑了每种细胞计数标志物和细胞遗传学数据：41位患者（11位CLL，30位非CLL）被分类，16位（占整个系列的2.7％）不能分类，被视为临界点LPD。除了临界LPD之外，CLLflow得分在这三种策略中具有最高的准确性。添加CD43后，没有患者被误分类。在分级聚类的帮助下，这16名边缘患者中有12名似乎分为两个明确的抗原组。没有一种诊断策略能够可靠地选择临界LPD。结论CLLflow评分和CD43的组合通常对白血病LPD具有较高的诊断准确性，但不能识别或诊断临界LPD。后一组需要进一步研究以确定其基础生物学。©2018国际临床细胞计量学会。16名边缘患者中有12名似乎属于两个明确的抗原组。没有一种诊断策略能够可靠地选择临界LPD。结论CLLflow评分和CD43的组合通常对白血病LPD具有较高的诊断准确性，但不能识别或诊断临界LPD。后一组需要进一步研究以确定其基础生物学。©2018国际临床细胞计量学会。16名边缘患者中有12名似乎属于两个明确的抗原组。没有一种诊断策略能够可靠地选择临界LPD。结论CLLflow评分和CD43的组合通常对白血病LPD具有较高的诊断准确性，但不能识别或诊断临界LPD。后一组需要进一步研究以确定其基础生物学。©2018国际临床细胞计量学会。后一组需要进一步研究以确定其基础生物学。©2018国际临床细胞计量学会。后一组需要进一步研究以确定其基础生物学。©2018国际临床细胞计量学会。